Literature DB >> 24463718

Provider-initiated HIV testing and counselling for TB in low HIV prevalence settings: is it worthwhile?

Shuko Nagai1, Roland Robinson, Jacky Ranaivo Rahamefy, Sahondra Jeannine Randriambeloson, Denis Andriatahina Ranaivomanana, Turibio Razafindranaivo, Liva Rakotobe, Adeline Ranaivo, Sven Gudmund Hinderaker, Anthony D Harries, Rony Zachariah.   

Abstract

BACKGROUND: We assessed the HIV-positive yield of offering provider-initiated HIV testing and counselling (PITC) for TB and the costs, in Madagascar, which has a low HIV prevalence and a high TB burden.
METHODS: A cross-sectional study of routinely collected records from January 2010 to June 2011.
RESULTS: A total of 37 596 TB patients were registered in 205 TB centres. HIV testing was available in 95 (46%) of centres where 7524 (40%) of those offered testing accepted it. Only 35 (0.5%) individuals were found HIV positive. Initial costs were about US$1.4 million and annual recurrent costs about US$0.1 million.
CONCLUSION: There are concerns of cost investment for countrywide introduction of PITC in a low HIV prevalence setting.

Entities:  

Keywords:  HIV; Operational research; Provider-initiated HIV testing and counselling; TB; WHO

Mesh:

Year:  2014        PMID: 24463718     DOI: 10.1093/trstmh/trt116

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  2 in total

1.  HIV testing uptake and HIV positivity among presumptive tuberculosis patients in Mandalay, Myanmar, 2014-2017.

Authors:  Khine Wut Yee Kyaw; Nang Thu Thu Kyaw; Myo Su Kyi; Sandar Aye; Anthony D Harries; Ajay M V Kumar; Nay Lynn Oo; Srinath Satyanarayana; Si Thu Aung
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

2.  Psychosocial beliefs related to intention to use HIV testing and counselling services among suspected tuberculosis patients in Kassala state, Sudan.

Authors:  Almutaz M Idris; Rik Crutzen; H W Van den Borne
Journal:  BMC Public Health       Date:  2021-01-07       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.